O2-ICU: Optimal Oxygenation in the Intensive Care Unit

Sponsor

Amsterdam UMC, location VUmc (Other)

Overall Status

Completed

CT.gov ID

NCT02321072

Collaborator

ZonMw: The Netherlands Organisation for Health Research and Development (Other), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other), Tergooi Hospital (Other)

400

Enrollment

Location

Arms

50.9

Actual Duration (Months)

7.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Objectives:

To study the short- and long-term effect of two different PaO2 targets on circulatory status, organ dysfunction and outcome in patient admitted to the ICU with Systemic Inflammatory Response Syndrome (SIRS) criteria.
To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response between the hyperoxic and the normoxic patients.

Study design:

Randomized, prospective multicentre clinical trial

Study population:

Patients admitted to the Intensive Care unit with ≥ 2 positive SIRS-criteria and an expected ICU stay of more than 48 hours

Intervention:

Group 1: target PaO2 120 (105 - 135) mmHg (high-normal)

Group 2: target PaO2 75 (60 - 90) mmHg (low-normal)

Primary endpoints:

The primary endpoint will be cumulative daily delta SOFA score (CDDS) from day 1 to day 14.

Condition or Disease	Intervention/Treatment	Phase
Systemic Inflammatory Response Syndrome	Drug: Oxygen	Phase 4

Detailed Description

Rationale:

Contrary to hypoxia, many physicians do not consider hyperoxia harmful for their patients. To prevent hypoxia, superfluous administration of oxygen is common practice, and hyperoxia is seen in many patients, especially on Intensive Care units. However, an increasing number of studies not only confirm the known negative pulmonary effects of chronic oxygen oversupply, but also important and more acute circulatory effects, characterised by decreased cardiac output (CO), increased systemic vascular resistance (SVR), and impaired microvascular perfusion. These phenomena can impair perfusion of organs, which may outweigh higher arterial oxygen content, resulting in a net loss of oxygen delivery and perturbed organ function. This may for example be responsible for hyperoxia-associated increased infarct size and increased mortality after myocardial infarction and cardiac arrest. The underlying mechanisms are not clarified yet, but probably involve increased oxidative stress with systemic vasoconstriction.

On the other hand, hyperoxia can also induce several favourable effects. The majority of ICU-patients have a systemic inflammatory response syndrome (SIRS) with concomitant vasoplegia due to trauma, sepsis or ischemia/reperfusion injury. Vasoconstriction could benefit these patients with severe SIRS, reducing the need for intravenous volume resuscitation and vasopressor requirements. Furthermore, hyperoxia may exert a preconditioning effect in patients with ischemia/reperfusion injury and prevent new infections due to its antibacterial properties.

Hypothesis:

Hyperoxia during SIRS ultimately has unfavourable effects on organ function, especially on a longer term.

Objectives:

To study the short- and long-term effect of two different PaO2 targets on circulatory status, organ dysfunction and outcome.
To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response between the hyperoxic and the normoxic patients.

Study design:

Randomized, prospective multicentre clinical trial

Study population:

Patients admitted to the Intensive Care unit with ≥ 2 positive SIRS-criteria and an expected ICU stay of more than 48 hours

Intervention:

We will investigate 2 groups with PaO2 targets both within the range of current practice

Group 1: target PaO2 120 (105 - 135) mmHg (high-normal)

Group 2: target PaO2 75 (60 - 90) mmHg (low-normal)

Study Design

Study Type:

Interventional

Actual Enrollment :

400 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Supportive Care

Official Title:

The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS

Actual Study Start Date :

Feb 1, 2015

Actual Primary Completion Date :

Jan 1, 2019

Actual Study Completion Date :

May 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: High-normal PaO2 In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).	Drug: Oxygen
Active Comparator: Low-normal PaO2 In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).	Drug: Oxygen

Arm

Intervention/Treatment

Active Comparator: High-normal PaO2

In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).

Drug: Oxygen

Active Comparator: Low-normal PaO2

In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).

Drug: Oxygen

Outcome Measures

Primary Outcome Measures

Daily Delta Sequential Organ Failure Assessment Score [14 days]
The primary endpoint will be cumulative daily delta SOFA score (CDDS) from day 1 to day 14, calculated as the sum of [daily SOFA score minus admission SOFA score] from day 2 to day 14. Daily SOFA score is calculated as the total of maximum scores for each organ system excluding respiratory system (because of possible PaO2/FiO2 distortion). For patients discharged from the ICU, SOFA score will be registered as 0 from the day of discharge to day 14. Death in the ICU will be registered as a score of 20 (maximum) from the day of death to day 14.

Secondary Outcome Measures

total maximum SOFA score minus SOFA score on admission [14 days]
SOFA rate of decline [14 days]
Total maximum SOFA score, total maximum SOFA score minus SOFA score on admission, SOFA rate of decline [14 days]
Mortality [14 days, in-ICU (max 90 days), in-hospital (max 90 days)]
Hypoxic events (PaO2 <55 mmHg) [14 days]
Vasopressor / Inotrope requirements [14 days]
Renal function, fluid balance [14 days]
Oxidative stress (F2-isoprostanes) [days 1, 3, 7]
Duration of mechanical ventilation and ventilator-free days [14 days]
Length of stay (ICU) [average expected 2 to 28 days]
Length of stay (hospital) [average expected 10 to 28 days]
Systemic Vascular Resistance Index [14 days]
In a random subpopulation.
Cardiac Index [14 days]
In a random subpopulation.
Microcirculatory flow index and Perfused vessel density [14 days]
In a random subpopulation. Composite endpoint for two sidestream dark-field microcirculatory measurements.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

≥2 positive SIRS-criteria:
Temperature >38 deg.C or hypothermia <36 deg.C
Heart rate >90 bpm
Respiratory rate >20 /min or pCO2 <32 mmHg (4.3 kPa)
Number of leucocytes >12 x 10^{9/l of <4 x 10}9/l of >10% bands
Within 12 hours of admittance to the ICU
Expected stay of more than 48 hours as estimated by the attending physician

Exclusion Criteria:

Elective surgery
Carbon monoxide poisoning
Cyanide intoxication
Methemoglobinemia
Sickle cell anemia
Severe pulmonary arterial hypertension (WHO class III or IV)
Known severe Acute Respiratory Distress Syndrome (ARDS) (PaO2/FiO2 ≤100 mmHg and PEEP ≥ 5 cm H2O)
Known cardiac right to left shunting
Pregnancy
Severe Chronic Obstructive Pulmonary Disease (COPD) (Gold class III or IV) or other severe chronic pulmonary disease
Patients participating in other interventional trials